Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
deals
fda
3
×
life sciences
national blog main
boston blog main
boston top stories
clinical trials
alexion pharmaceuticals
alirocumab
alnylam pharmaceuticals
amgen
amyotrophic lateral sclerosis (als)
autoimmune disorders
boston
complement system
evolocumab
food and drug administration
generalized myasthenia gravis
immune-mediated necrotizing myopathy
inclisiran
medical device
national top stories
new york
new york blog main
new york top stories
novartis
pcsk9
pcsk9 inhibitors
pulmonary arterial hypertension
ra pharmaceuticals
raleigh-durham blog main
rare disease drugs
regeneron pharmaceuticals
rna interference
san francisco
san francisco blog main
san francisco top stories
sanofi
startups
What
deal
3
×
drug
3
×
disease
medicines
acquire
agreed
alternative
autoimmune
billion
brings
building
candidate
cash
cholesterol
company
compound
developer
established
expensive
fda
firm
lead
lung
medco
momentum
new
novartis
pah
pharma
pharmaceuticals
poised
potential
ra
rare
reaches
ready
rivalry
seller
stakes
steadymed
Language
unset
Current search:
deal
×
fda
×
drug
×
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
6 years ago
United Therapeutics Reaches $141M Deal for PAH Drug Firm SteadyMed
